PTO-1449 REPRODUCED

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

November 4, 2005

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.	
2316.2009-000	10/786,380	
FIRST NAMED INVENTOR	FILING DATE	
Mary Jane Cardosa	February 24, 2004	
EXAMINER	CONFIRMATION NO.	GROUP
Not Yet Assigned	3579	1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
MM	A1	5,185,146	02-09-1993	Altenburger, W.
	A2	5,221,601	06-22-1993	Montagnier, *et al.*
	A3	5,514,375	05-07-1996	Paoletti *et al.*
	A4	5,676,950	10-14-1997	Small, Jr., *et al.*
	A5	5,679,511	10-21-1997	Kwon
	A6	5,744,140	04-28-1998	Paoletti *et al.*
	A7	5,744,141	04-28-1998	Paoletti *et al.*
	A8	6,440,422 B1	08-27-2002	Sutter, Gerd
	A9	US-2003-0035792-A1	02-20-2003	Sutter, Gerd

EXAMINER	DATE CONSIDERED
/Mary Mosher/	09/18/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	2316.2009-000	10/786,380	
November 4, 2005	FIRST NAMED INVENTOR: Mary Jane Cardosa	FILING DATE: February 24, 2004	
(Use several sheets if necessary)	EXAMINER: Not Yet Assigned	CONFIRMATION NO.: 3579	GROUP: 1642

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
MM	B4	CH 568 392	10-31-1975	Bayern Freistaat		X
	B2	EP 0 110 385 B1	02-17-1993	The United States of America		
	B3	EP 0 198 328 B1	07-01-1992	F. Hoffmann-La Roche AG		
	B4	EP 0 324 350 A1	07-19-1989	F. Hoffmann-La Roche AG		X
	B5	WO 92/03545 A1	03-05-1992	Virogenetics Corp (US)		
	B6	WO 92/03545 A1 (Corrected Version)	03-05-1992	Virogenetics Corp (US)		
	B7	WO 96/40933 A1	12-19-1996	US Health (US), *et al.*		
	B8	WO 97/44447 A2	11-27-1997	President and Fellows of Harvard College (US)		
	B9	WO 98/13500 A2	04-02-1998	Bavarian Nordic Research Institute A/S, *et al.*		
	B10	WO 99/15692 A2	04-01-1999	Bavarian Nordic Research Institute A/S, *et al.*		

EXAMINER	/Mary Mosher/	DATE CONSIDERED	09/18/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2316.2009-000	APPLICATION NO. 10/786,380	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Mary Jane Cardosa	FILING DATE February 24, 2004	
November 4, 2005	EXAMINER Not Yet Assigned	CONFIRMATION NO. 3579	GROUP 1642
(Use several sheets if necessary)			

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
MM	C1	Altenburger, W., *et al.*, "Partial Deletion of the Human Host Range Gene in the Attenuated Vaccinia Virus MVA," *Arch. Virol., 105*:15-27 (1989).
	C2	Borsani, *et al.*, "Characterization of a Human and Murine Gene (CLCN3) Sharing Similarities to Voltage-Gated Chloride Channels and to a Yeast Integral Membrane Protein", *Genomics 27*:131-141 (1995).
	C3	Bowie, *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", *Science 257*:1306-1310 (1990).
	C4	Bray, M., et al., "Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins With or Without Nonstructural Protein NS1 Are Protected Against Fatal Dengue Virus Encephaliti," *J. Virol. 63*(6):2853-2856 (1989).
	C5	Cardosa, M.J., "Dengue vaccine design: issues and challenges," British Medical Bulletin, 54(2): 395-405 (1998).
	C6	Carroll, M.W., *et al.*, "E. Coli β-glucuronidase (GUS) as a marker for recombinant vaccinia viruses", *Biotechniques, 19*:352-355 (1995).
	C7	Chakrabarti, *et al.*, "Vaccinia Virus Expression Vector: Coexpression of β-Galactosidase Provides Visual Screening of Recombinant Virus Plaques," *Molecular and Cellular Biology 5*:3403-3409 (1985).
	C8	Chambers, T.J., *et al.*, "Flavivirus Genome Organization, Expression, and Replication," *Annu. Rev. Micorobiol.* 44:649-688 (1990).
	C9	Cruse, *et al., Illustrated Dictionary of Immunology,* CRC Press, Boca Raton, pages 102-103 (1995).
	C10	Deroo, S., *et al.*, "Antigenic and Immunogenic Phage Displayed Mimotopes as Substitute Antigens: Applications and Limitations," *Combinatorial Chemistry & High Throughput Screening 4*:75-110 (2001).
	C11	Eckels, *et al.*, "Immunization of Monkeys with Baculovirus-Dengue Type-4 Recombinants Containing Envelope and Nonstructural Proteins: Evidence of Priming and Partial Protection", *American Journal of Tropical Medicine and Hygiene 50*:472-478 (1994).
↓	C12	Falconar, A.K.I., *et al.*, "Precise location of sequential dengue virus subcomplex and complex B cell epitopes on the nonstructural-1 glycoprotein," *Archives of Virology*, 137: 315-326(1994).

EXAMINER	/Mary Mosher/	DATE CONSIDERED	09/18/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2316.2009-000	APPLICATION NO. 10/786,380	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Mary Jane Cardosa	FILING DATE February 24, 2004	
November 4, 2005	EXAMINER Not Yet Assigned	CONFIRMATION NO. 3579	GROUP 1642
(Use several sheets if necessary)			

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
MM	C13	Falgout, *et al.*, "Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NS1 Protects against Lethal Dengue Virus Encephalitis," *J. Virol. 64*:4356-4363 (1990).
	C14	Fonseca, BA., et al., "Recombinant Vaccinia Viruses Co-Expressing Dengue-1 Glycoproteins PreM and E Induce Neutralizing Antibodies in Mice," *Vaccine 12*(3):279-285 (1994).
	C15	Greenspan, *et al.*, "Defining Epitopes: It's not as easy as it seems," *Nature Biotechnology 7*:936-937 (1999).
	C16	Gruenberg, *et al.*, "Partial Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains," *J. Gen. Virol. 69*:1391-1398 (1988).
	C17	Hiramatsu, K., et al., "Mutational Analysis of a Neutralization Epitope on the Dengue Type 2 Virus (DEN2) Envelope Protein: Monoclonal Antibody Resistant DEN2/DEN4 Chimeras Exhibit Reduced Mouse Neurovirulence," *Virology 224*(2):437-445 (1996).
	C18	Hirsch, V.M., *et al.*, "Limited Virus Replication Following SIV Challenge of Macaques Immunized with Attenuated MVA Vaccinia Expressing SIVsm *env* and *gag-pol*," Vaccines 95, *Cold Spring Harbor Laboratory Press, USA*, pgs. 195-200 (1995).
	C19	Hirsch, V.M., *et al.*, "Patterns of Viral Replication Correlate with Outcome in Simian Immunodeficiency Virus (SIV)-Infected Macaques: Effect of Prior Immunization with a Trivalent SIV Vaccine in Modified Vaccinia Virus Ankara," *J. Virol., 70(6)*:3741-3752 (1996).
	C20	Henchal, E.A., *et al.*, "Synergistic Interactions of Anti-NS1 Monoclonal Antibodies Protect Passively Immunized Mice from Lethal Challenge with Dengue 2 Virus," *J. Gen. Virol. 69*:2102-2107 (1988).
	C21	Jianmin, Z., et al., "Analysis of Functional Epitopes on the Dengue 2 Envelope (E) Protein Using Monoclonal IgM Antibodies," *Arch Virol. 140*(5):899-913 (1995).
	C22	Mackett, *et al.*, "General Method for Production and Selection of Infectious Vaccinia Virus Recombinants Expressing Foreign Genes," *J. Virol. 49*:857-864 (1984).
	C23	Mayr, A., *et al.*, "The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained with the Parenteral Vaccination and Behavior in Organisms with a Debilitated Defence Mechanism," *Zbl. Bakt. Hyg., I Abt. Org. B, 167*:375-390 (1978).

EXAMINER /Mary Mosher/	DATE CONSIDERED 09/18/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	2316.2009-000	10/786,380	
November 4, 2005	FIRST NAMED INVENTOR: Mary Jane Cardosa	FILING DATE: February 24, 2004	
(Use several sheets if necessary)	EXAMINER: Not Yet Assigned	CONFIRMATION NO.: 3579	GROUP: 1642

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
MM	C24	Mayr, A., *et al.*, "Abstammung, Eigenschaften und Verwendung des Attenuierten Vaccinia-Stammes MVA," *Infection, 3*:6-14 (1975).
	C25	Megret, *et al.*, "Use of Recombinant Fusion Proteins and Monoclonal Antibodies to Define Linear and Discontinuous Antigenic Sites on the Dengue Virus Envelope Glycoprotein", *Virology 187*:480-491 (1992).
	C26	Meyer, H., *et al.*, "Mapping of Deletions in the Genome of the Highly Attenuated Vaccinia Virus MVA and their Influence on Virulence," *J. Gen. Virol., 72*:1031-1038 (1991).
	C27	Moss, B., *et al.*, "New mammalian expression vectors," *Nature 348*(6296): 91-92 (1990).
	C28	NTIS Accession Number PB, 88201363, "Novel Recombinant Vaccinia Virus Expression Vectors and Method of Selecting Same".
	C29	NTIS Accession Number PB89144802, "Novel Inhibitor of HIV Infection".
	C30	NTIS Accession Number PB88192059, " A Synthetic Antigen Evoking Anti-HIV Response".
	C31	Pupo-Antunez, Maritza *et al.*, "Monoclonal Antibodies Raised to the Dengue-2 Virus (Cuban: A15 Strain) Which Recognize Viral Structural Proteins," *Hybridoma*, 16(4): 347-353 (1997).
	C32	Scheiflinger, *et al.*, "Evaluation of the Thymidine Kinase (TK) Locus as an Insertion Site in the Highly Attenuated Vaccinia MVA Strain," *Arch. Virol. 141*:663-669 (1996).
	C33	Smucny, JJ., et al., "Murine Immunoglobulin G Subclass Responses Following Immunization With Live Dengue Virus or a Recombinant Dengue Envelope Protein," *Am J. Trop Med. Hyg. 53*(4):432-437 (1995).
	C34	Stickl, H., *et al.*, "MVA-Stufenimpfung Gegen Pocken" *Dtsch. Med. Wschr., 99*:2386-2392 (1974).
	C35	Sutter, G., *et al.*, "A Recombinant Vector Derived from the Host Range-Restricted and Highly Attenuated MVA Strain of Vaccinia Virus Stimulates Protective Immunity in Mice to Influenza Virus," *Vaccine, 12(11)*:1032-1040 (1994).
↓	C36	Sutter, G. and Moss, B., "Nonreplicating Vaccinia Vector Efficiently Expresses Recombinant Genes," *Proc. Natl. Acad. Sci., USA, 89*:10847-10851 (1992).

EXAMINER	DATE CONSIDERED
/Mary Mosher/	09/18/2006

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	2316.2009-000	10/786,380	
November 4, 2005	FIRST NAMED INVENTOR	FILING DATE	
(Use several sheets if necessary)	Mary Jane Cardosa	February 24, 2004	
	EXAMINER	CONFIRMATION NO.	GROUP
	Not Yet Assigned	3579	1642

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
MM	C37	Sutter, G., et al., "Non-Replicating Vaccinia Vector Efficiently Expresses Bacteriophage T7 RNA Polymerase," FEBS Letters 371:9-12 (1995).
	C38	Sutter, G. and Moss, B., "Novel Vaccinia Vector Derived from the Host Range Restricted and Highly Attenuated MVA Strain of Vaccinia Virus," *Dev. Biol. Stand. Basel, Karger, 84*:195-200 (1995).
	C39	Svrivastava, *et al.*, "Mice Immunized with a Dengue Type 2 Virus E and NS1 Fusion Protein Made in *Escherichia coli* are Protected Against Lethal Dengue Virus Infection," Vaccine *13*:1251 (1995).
	C40	Venugopal, K., *et al.*, "Towards a New Generation of Flavivirus Vaccines," *Vaccine 12*:11-20 (1994).
	C41	Wang, S., et al., "Antibody-Enhanced Binding of Dengue-2 Virus to Human Platelets," *Virology 213*(1):254-257 (1995).
	C42	Wyatt, *et al.*, "Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells", *Virol., 210*:202-205 (1995).
	C43	Zhao, *et al.*, "Cloning Full-Length Dengue Type 4 Viral DNA Sequences: Analysis of Gene Coding for Structural Proteins," *Virology 155*:77-88 (1986).
↓	C44	Zhao, *et al.*, "Expression of Dengue Virus Structural Proteins and Nonstructural Protein NS_1 by a Recombinant Vaccinia Virus," *J. Virol. 61*:4019-4022 (1987).

EXAMINER	DATE CONSIDERED
/Mary Mosher/	09/18/2006